ClinicalTrials.gg
RecruitingNCT07161908Updated Nov 3, 2026

Controlled Remote Monitoring and Optimization of Oxygen Therapy in Preterm Infants

An interventional study of Pulse oximeter in BPD - Bronchopulmonary Dysplasia and Pulmonary Hypertension, sponsored by Institute of Health Information and Statistics of the Czech Republic. Recruiting at 4 sites in Czechia. Open to participants aged Up to 36 Weeks. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Institute of Health Information and Statistics of the Czech Republic · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
Up to 36 Weeks
Sex
All
01

Study summary

The project is a national, prospective, multicenter, interventional pilot project focused on controlled remote monitoring and optimization of oxygen therapy for premature infants in the Czech Republic. The primary aim of the project is to prepare, test, and develop a proposal for a national methodology for the care of preterm newborns. This will reduce health risks in premature infants and minimize the negative impacts on the overall development of the child and the family of the premature infant.

Read the detailed description

The project is a national, prospective, multicenter, interventional pilot project focused on remote monitoring and optimization of oxygen therapy for premature infants in the Czech Republic.

The main goal of the project is validation of the possibility and organization of remotely managed home oxygen therapy and its optimization, aiming for its earlier termination.

The project will be running in 4 perinatology centers in the Czech Republic. It is expected that 70 premature infants diagnosed with bronchopulmonary dysplasia will participate. The infant must transition to low-flow nasal cannulas to be discharged to home care. Oxygen therapy will be adjusted based on pre-established protocols aiming for earlier and safer termination of oxygen therapy through precise remote continual monitoring.

The project is supported by the European Social Fund (Operational Program Employment Plus) and the state budget of the Czech Republic and is registered by the Ministry of Labour and Social Affairs of the Czech Republic under ID: CZ.03.02.02/00/22_005/0002020.

The study has been reviewed and approved by multiple local ethical committees. The listed IRB represents the lead national ethical committee overseeing the trial.

02

Conditions studied

  • BPD - Bronchopulmonary Dysplasia
  • Pulmonary Hypertension

Keywords

  • BPD
  • Bronchopulmonary Dysplasia
  • preterm infants
  • oxygen therapy
  • telemedicine
  • remote monitoring
  • pulmonary hypertension
  • Czech Republic
03

In context

Bronchopulmonary Dysplasia

363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.

This study's planned enrollment of 70 is close to the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

Institute of Health Information and Statistics of the Czech Republic is the lead sponsor of 14 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infants born before 31+6 weeks gestation
  • signed consent for participation in the project and consent for the processing of personal data
  • diagnosed with bronchopulmonary dysplasia
  • type of pulmonary ventilation - low-flow nasal cannulas

Exclusion criteria

Exclusion Criteria:

  • unsigned consent for participation in the project and/or consent for the processing of personal data
  • child diagnosed with conditions other than bronchopulmonary dysplasia (BPD) at high risk of long-term hypoxia - selected chronic cardiovascular, neurological, and muscular diseases, e.g., significant congenital heart defects, congenital central nervous system developmental disorders, genetic diseases associated with the risk of hypoventilation, central apneas, severe early obstructive sleep apnea
  • other chronic respiratory diseases besides BPD - e.g., cystic fibrosis, chronic aspiration
  • insufficient therapy through long-term home oxygen therapy
  • tracheostomy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Controlled remote oxygen therapy

    The patients will be following study protocol of optimization of oxygen therapy.

    Device: Pulse oximeter

Interventions

  • DevicePulse oximeter

    To ensure proper treatment, the infant will be continuously monitored with a pulse oximeter. Based on oxygen saturation levels, the treatment may be adjusted according to pre-established protocols. It is required that the saturation stays above a certain value for more than 95 % of the 12-hour measurement period. If the defined saturation values are reached, the parents will reduce the oxygen flow by one degree for 20 minutes in the hospital/home setting (20 minute test) and if the saturation values remain at 93 % or more during this period, overnight 12 hour monitoring will also be performed to confirm stable saturation values of 93 % or more for 95 % or more of the monitoring time. Thanks to modern specialized pulse oximeters, it is possible to ensure accurate, long-term, remotely managed monitoring of the infant and to interactively optimize oxygen therapy based on current oxygen saturation levels.

06

What researchers measure

Primary outcomes

  1. Average duration of controlled oxygen therapy in a premature infant

    Number of days a premature infant stays on oxygen therapy

    Time frame: From the enrollment to 4 weeks after discontinuation of home oxygen therapy application in child (complete weaning from oxygen supply)

Secondary outcomes

  1. Average number of failures in premature infants before the termination of controlled oxygen therapy

    Failure is defined as the need to return to the original flow rate before the last reduction.

    Time frame: From the enrollment to 4 weeks after discontinuation of home oxygen therapy application in child (complete weaning from oxygen supply)

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2027, 20 months after the start.

Of 71 non-industry interventional studies with no phase under Bronchopulmonary Dysplasia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 20 months is below that.

Counting every sponsor, half of 73 studies reached it within 37 months; a quarter within 19 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Nov 2026 → Apr 2027 and completion Feb 2027 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Sep 9, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Apr 2027was Nov 2026
CompletionEst.
Aug 2027was Feb 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Apr 2027
Nov 3, 2026
Study completion
Feb 2027→Aug 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Nov 2026→Apr 2027
    Study completion Feb 2027→Aug 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07161908
Lead sponsor
Institute of Health Information and Statistics of the Czech Republic
Collaborators
České Budějovice Hospital, University Hospital Olomouc, Institute for the Care of Mother and Child, Prague, Czech Republic, General University Hospital, Prague
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Aug 25, 2025
Primary completion
Apr 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Daniela Dokoupilová, MSc
Contact
daniela.dokoupilova@uzis.cz
+420725441408
Lucie Mandelová, Ph.D.
Contact
lucie.mandelova@uzis.cz
+420770190828
Richard Plavka, prof.
study director · General Hospital University in Prague
Jana Tuková, Ph.D.
study chair · General Hospital University in Prague

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion